BB Biotech AG : Portfolio update: Target price revised up to € 64, Neutral recommendation maintained
>A Q2 2019 marked by concerns in the US and a negative forex effect - BB Biotech reported its Q2 2019 results on Friday, 19 July, the holding company’s share price declined by 4.8% over the quarter in euros and in Swiss francs marginally underperforming its benchmark index NBI (Nasdaq Biotechnology Index), which shed 4% in euro over the period. NAV for the portfolio declined by 9.4% in Swiss francs, by 8.8% in euros and by 7.6% in dollars. This resulted in a net loss ...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.